Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.
Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.
A set of 1349 patients completed a self-administered questionnaire on environmental, food, and drug allergies, and they were distributed among 4 allergy groups: environmental (n = 586), food (n = 238), drug (n = 574), and no known allergies (NKA; n = 427).
The researchers then assessed clinical variables—the number of attacks, expanded disability status scale (EDSS), and MS severity score (MSSS)—and radiological variables—presence of gadolinium-enhancing lesions and lesion count—and the association of these variables with the different allergy groups.
"Our findings suggest that MS patients with allergies have more active disease than those without, and that this effect is driven by food allergies," wrote the researchers.
Compared with the NKA group, patients with food allergies had a 1.38 times higher rate for cumulative number of attacks (P = .0062). The food allergy group also showed more than twice the likelihood (P = .0096) of having gadolinium-enhancing lesions on magnetic resonance imaging than the NKA group.
The initial analysis indicated that any allergy was associated with a 22% higher rate of cumulative disease bouts compared with NKA, but that difference disappeared after taking into account potentially influential factors.
“Future prospective studies are needed to confirm our findings and investigate underlying biological mechanisms, which may unveil new therapeutic and preventative strategies for MS,” the authors concluded.
Reference
Fakih R, Diaz-Cruz C, Chua AS, et al. Food allergies are associated with increased disease activity in multiple sclerosis [published online December 18, 2018]. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2018-319301.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More